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Abstract
Background: Current guidelines suggest reduction of DMARDs can be considered in RA patients in remission.
Objectives were (1) to estimate the relative importance of patient characteristics rheumatologists consider in their
decision to de-escalate (2) to assess whether heterogeneity exists among rheumatologists with respect to de-
escalation and (3) to identify the preferred de-escalation strategy.
Methods: A discrete choice experiment (DCE) was conducted. All rheumatologists and trainees in The Netherlands
were invited to participate. A conditional logit model was estimated to assess overall preference for de-escalation
and its determinants. Heterogeneity was estimated by latent class analysis.
Results: The DCE questionnaire was completed by 156 doctors. This questionnaire was constructed using the
results of semi-structured interviews with 12 rheumatologists that identified five patient characteristics relevant for
de-escalation: number of swollen joints (SJC), presence of DAS remission/low disease activity (LDA), patient history,
duration of remission/LDA and patient willingness to de-escalate DMARDs. Overall SJC and patient history were
most important. Latent class analysis revealed five subgroups of doctors, showing differences regarding willingness
to de-escalate and relative importance of patient characteristics. De-escalation of the TNF inhibitor rather than
methotrexate first was the most preferred strategy.
Conclusions: Rheumatologists are not uniform in their decision on whom to de-escalate. Differences emerged in
which characteristics they traded off resulting in five subgroups: those that taper (1) always, (2) in absence of
swollen joints, (3) in absence of swollen joints and presence of favorable patient history, (4) in DAS remission and
favorable patient history, and (5) taking into account all factors.
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Background
Treatment of rheumatoid arthritis (RA) has advanced
greatly during the past decades. The introduction of com-
bination therapy with disease-modifying anti-rheumatic
drugs (DMARDs), the recognition of early, tightly con-
trolled treatment, and the introduction of biologic agents
have contributed to improved outcomes for patients
suffering from RA [1]. With intensive use of (a combin-
ation of) DMARDs, a state of low disease activity (LDA)
or remission can be achieved by many patients while
preventing erosions and functional impairment [2, 3].
Although DMARD therapy is essential to obtain disease
control, continuous use comes with several disadvantages.
Apart from obvious drawbacks such as drug toxicity and
side effects, medication use by itself may be perceived as
burdensome and unhealthy by patients. Hence many
patients view medication use as a necessary burden and
wish to minimize its use. Also medication costs, especially
for expensive biological treatments, are of increasing
concern for governments. From this viewpoint tapering or
discontinuation of DMARDs is preferable once disease
control has been obtained.
Current guidelines suggest that reduction of biological
(b)DMARDs can be considered, especially if this treatment
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is combined with a conventional synthetic (cs)DMARD,
once sustained remission has been achieved and glucocor-
ticoids have been tapered first [4, 5]. In addition, guidelines
state that a cautious reduction of csDMARDs could be
considered, as a shared decision between patient and
physician, after glucocorticoids and bDMARDs have been
successfully withdrawn [5]. Furthermore, a general recom-
mendation is included that, apart from disease activity,
other factors should be taken into account such as
progression of structural damage, comorbidities, and safety
issues [5].
Indeed, evidence from a range of clinical studies sug-
gests that de-escalation of DMARDs is feasible in a large
number of patients in LDA or disease remission [6–8].
However, to date there is no standardized way to deter-
mine the patient for whom de-escalation of DMARD
therapy is appropriate [8]. Also, adherence of rheumatol-
ogists to the guidelines that are currently available for
de-escalation may not be optimal [9]. Therefore large
differences are expected to exist between rheumatolo-
gists with respect to whether, when, and in which pa-
tients they will de-escalate therapy. Obtaining insight in
these differences may assist in future guideline develop-
ment and guide further research into this topic. In the
assessment whether a patient is a suitable candidate for
treatment de-escalation, rheumatologists weigh several
patient characteristics together at the same time. Hence
a simple questionnaire in which the importance of pa-
tient characteristics is rated separately does not reflect a
real-life decision. A discrete choice experiment (DCE) is
a method that allows for the analysis of such complex
decisions. It does so by presenting a series of “choice
tasks” to the participant. Each choice task consists of
two hypothetical patients with varying characteristics.
The participant must then choose the patient with the
most favorable combination of characteristics. By analyz-
ing the choices participants made based on the character-
istics, the relative importance of patient characteristics on
the decision to de-escalate treatment can be assessed. A
technique very similar to that of a discrete choice ex-
periment was used in the process of the development
of the American College of Rheumatology/European
League Against Rheumatism (ACR/EULAR) 2010 cri-
teria for RA [10].
Objectives of this study were (1) to estimate the relative
importance of patient characteristics rheumatologists con-
sider in their decision to de-escalate medication, (2) to
quantify how these characteristics influence doctor’s
preferences for de-escalating DMARDs, (3) to assess
whether heterogeneity exists among rheumatologists
with respect to their preference for de-escalation and
the patient characteristics influencing this decision,
and (4) to identify the most preferred de-escalation
strategy.
Methods
DCE
In a DCE it is assumed that the analyzing process lead-
ing to a decision to medically intervene, such as de-
escalation of medication, can be described by features
relevant for making that decision (patient and disease
characteristics) [11, 12]. In the case of a rheumatologist
deciding whether to de-escalate DMARDs for a certain
patient, these characteristics are likely disease related
(e.g., presence of swollen joints indicating active disease).
Each characteristic can then be further described by spe-
cific variants or levels (e.g., presence of no, one or two
swollen joints) [11, 12]. Another assumption is that an
individual’s preference for the intervention is determined
by the levels of these characteristics [11, 12]. By offering
a series of choices between two options with different
characteristics (patients with different characteristics),
the relative importance of the characteristics on the
decision can be determined [11].
Questionnaire design
To identify patient characteristics that determine the
decision-making for DMARD de-escalation, 12 rheuma-
tologists were randomly selected for interviews stratified
by region and type of hospital (university or general). A
semi-structured interview schedule (Additional file 1)
was designed based on characteristics identified by pilot
interviews of rheumatologists and literature [7]. During
the semi-structured interviews, rheumatologists were
questioned by telephone about their personal opinion
and attitude with respect to DMARD de-escalation. The
number of interviews was deemed sufficient as no new
themes were mentioned during the final interviews, and
therefore no other rheumatologists were approached.
Based on the interviews, five patient characteristics with
corresponding levels were developed (Table 1).
Study design and questionnaire
A questionnaire containing 16 choice tasks, each con-
sisting of two hypothetical patients, was deemed feasible
to complete by rheumatologists attending the annual
convention of the Dutch Society of Rheumatology
(Nederlandse Vereniging voor Reumatologie, NVR). All
hypothetical patients were assumed to use the combination
of methotrexate 20–25 mg/week and a tumor necrosis fac-
tor (TNF) blocker, without additional glucocorticoids. In
order to gain as much information as possible (enhancing
precision) from a limited number of choice sets and
sample size, computer software using experimental design
theory (Ngene 1.1.2, 2014 ChoiceMetrics software, Sydney,
NSW, Australia) was used to generate the most efficient
sets of choices given the characteristics as defined previ-
ously (optimized for a main effect model with full dummy
specification). To further optimize this process, priors were
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chosen reflecting the expected direction of characteristic
levels on preference (Additional file 2), but not imposing
any strong assumptions about the weight of each charac-
teristic in the decision that might (dis)favor identification
of some effects over others.
Choice sets consisted of two hypothetical patients and
an opt-out option (Additional file 3). From each choice
set, rheumatologists were asked to choose the patient
they deemed most suitable to de-escalate DMARDs. The
opt-out option was included in case respondents deemed
neither patient suitable for de-escalation, resembling
real-life decision-making. Of note, only after rheumatol-
ogists chose to de-escalate treatment in either patient
they were offered a second question to select the strat-
egy they most preferred. If de-escalation was deemed ap-
propriate, a second choice was given on how they would
de-escalate DMARDs. To make respondents familiar
with the concept of DCE, two introductory questions
were included. To avoid bias by presentation, the order
of choice sets and order of attributes were randomized
for each participant [13]. An English translation of a
complete questionnaire was included (Additional file 4).
Study sample
All rheumatologists and rheumatology trainees active in
the Netherlands were eligible for participation.
Invitation of subjects
A list of active rheumatologists was kindly provided by
the Dutch Society of Rheumatology (NVR). Doctors
were recruited during the annual meeting of the NVR
on 25 and 26 September 2014. Questionnaires were pro-
vided electronically on iPads. Non-attending rheumatol-
ogists received an invitation by e-mail to complete the
questionnaire at their own computer.
Statistical analyses
We estimated a conditional logit model to assess overall
preference for de-escalation of DMARDs and its deter-
minants (Additional file 5).
To assess whether preferences for de-escalation and
relative importance of patient characteristics determin-
ing this decision differed among rheumatologists, a
subgroup analysis (latent class model) was performed as
well (Additional file 3). With this model, subgroups of
rheumatologists (clusters or classes) can be identified.
To determine the optimal number of classes, we selected
the model with the best fit on the consistent Akaike in-
formation criterion (cAIC). This measure deals with the
trade-off between increase in goodness of fit of the
model and the increase in complexity by the addition of
clusters. Analyses were performed using the clogit and
lclogit function in STATA (version 13.1, StataCorp,
College Station, TX, USA).
Results
In total 156 doctors completed the questionnaire (128
rheumatologists and 28 trainees), 128 of which com-
pleted the questionnaire at the annual conference Of
174 rheumatologists that had not participated at the an-
nual conference and received an invitation by e-mail, 28
(16%) completed the questionnaire online. Eleven rheu-
matologists did not provide demographic data because
of technical problems or by their own wishes. Character-
istics of the study sample are shown in Table 2.
De-escalation of therapy was preferred in 74% of the pa-
tient choice sets evaluated by the rheumatologists. To
quantify how patient characteristics influence doctor’s
preferences for de-escalating DMARDs, a conditional logit
model was estimated (Table 3). The interpretation of such
a model is somewhat different than of a linear or logit re-
gression model. Each of the patient characteristics played
Table 1 Choice task example
Patient A Patient B
Duration of remission1 6 months 1 year
Patient preference for de-escalation at the start of the consult2 Patient is not willing to de-escalate Patient is willing to de-escalate
Number of swollen joints3 1 2
DAS284 ≤3.2 <2.6
Medical history5 Difficult to accomplish remission Easy to accomplish remission
Non-erosive Erosive
Participants were required to choose the patient they deemed most suitable for de-escalation or neither (opt-out). For each choice task patient characteristics
were varied by assigning different levels. Possible levels are indicated in the subscript. All patients were assumed to use the combination of methotrexate 20–
25 mg/week and a TNF blocker
DAS Disease Activity Score
1Levels were “6 months” and “12 months”
2Levels were “patient is not willing to de-escalate” and “patient is willing to de-escalate”
3Levels were “0”, “1” and “2”
4Levels were “≤3.2” and “<2.6”
5Levels were “difficult to accomplish remission, erosive”, “difficult to accomplish remission, non-erosive”, “easy to accomplish remission, erosive” and “easy to
accomplish remission, non-erosive”
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a role in the decision to de-escalate DMARDs, as all
coefficients of the model showed significance. The opt-out
option was chosen if a rheumatologist deemed neither
patient of a pair suitable for treatment de-escalation. De-
escalation was chosen in 74% of cases, while the opt-out
was chosen in 26% of cases. Therefore, in general, the opt-
out was less preferred than de-escalation (the reference
category), which is reflected by a negative sign for the opt-
out (Table 1). Coefficients for the other factors have a
similar interpretation, as will be further explained.
For each characteristic, we chose the level we expected
to be most preferable for de-escalation to be the refer-
ence level, e.g., no swollen joints, Disease Activity Score
(DAS) < 2.6 (see footnotes Table 3). Therefore, the ideal
patient that doctors would like to consider for de-
escalation of DMARDs is a patient having all the refer-
ence characteristics, i.e., came in remission easily, has no
erosions, a remission duration of 1 year, no swollen
joints, and has DAS remission rather than DAS LDA.
Hence, the coefficients represent the relative decrease in
de-escalation preference when a patient presents with
that feature (e.g., two swollen joints) relative to the refer-
ence of that feature (no swollen joints). Presence of two
swollen joints (-1.68, p < 0.001) and a patient history of
erosive disease in combination with difficulties achieving
remission (-1.64, p < 0.001) had the strongest influence
on the decision not to de-escalate (Table 3). It should be
emphasized that above results did not depend on the
fashion in which DMARDs were de-escalated, as this
was not specified in the questionnaire. Only after rheu-
matologists chose to de-escalate treatment in either
patient they were offered a second question to select the
strategy they most preferred (see below).
Although this model describes the preferences of rheu-
matologists for de-escalation of DMARDs on average, in
reality subgroups of doctors may exist that weigh patient
characteristics differently. Therefore we looked whether
we could distinguish subgroups based on answering
patterns. Using a latent class model, we identified five
subgroups of rheumatologists as shown in Table 4. Each
of the groups made different trade-offs in whom to de-
escalate DMARDs given the relative weight in the pa-
tient characteristics and opt-out. Opt-out preference
ranged from 1% in class 4 to 53% in class 5. For each
subgroup the relative weights of the patient characteris-
tics that drove de-escalation were analyzed (absolute
weights of coefficients cannot be directly compared be-
tween subgroups because coefficients are on different
scales). Table 4 shows that presence of swollen joints
was the most important characteristic for rheumatolo-
gists to consider in subgroups 2 and 5, whereas in sub-
groups 1 and 3 patient history was most important. Of
note, in subgroup 4 none of the patient characteristics
dominated the decision to de-escalate, while their prefer-
ence for de-escalation was strong. To further illustrate
differences between the subgroups, 96 unique patient
profiles were created, using the characteristics and levels
as defined in Table 1. As shown in Fig. 1, overall,
patients 1–10 had a high probability to be considered
for de-escalation (>80%) and patients 83–96 had a low
Table 2 Characteristics of study sample
Rheumatologists (n = 117)a Trainee (n = 28)
Age (years), median (IQR) 47 (40–57) 34 (31–36)
Female, n (%) 60 (51%) 20 (71%)
Work experience (years), median (IQR) 10 (5–23) -
Self-reported number of RA patients in practice, median (IQR) 350 (200–1000) 70 (25–100)
Self-reported prevalence of biological treatment among RA patients in practice, median (IQR) 25 (20–30) 30 (20–35)
Working in academic hospital, n (%) 19 (16%) 10 (36%)
aEleven out of 128 rheumatologists did not provide information due to technical problems or by their own wish
Table 3 Overall preference of doctors for de-escalation based
on a conditional logit model
Overall n = 156
β SE
Opt out1 chosen 26%
Opt out1 -2.96*** 0.11
DAS≤ 3.22 -0.98*** 0.07
Swollen joint count
13 -1.15*** 0.08
23 -1.68*** 0.09
Patient history
Erosive disease4 -0.69*** 0.11
Remission difficult4 -0.80*** 0.09
Erosive + remission difficult4 -1.64*** 0.10
Remission duration 6 months5 -0.52*** 0.06
Patient not willing to de-escalate at start of visit6 -1.09*** 0.07
β beta coefficient, SE standard error, DAS Disease Activity Score
***p < 0.001
1This option was included in case a rheumatologist did not want to de-
escalate DMARDs in either of the patients presented in a pair
2Reference DAS < 2.6
3Reference no swollen joints
4Reference easy remission and no erosions
5Reference remission duration 1 year
6Reference patient willing to de-escalate DMARDs at start of visit
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probability (<20%). For the other patients (11–82), prob-
abilities to be considered for de-escalation were variable
among subgroups. Comparing subgroups with respect to
their willingness to de-escalation, group 4 had the great-
est willingness to de-escalate and group 5 was least
willing to de-escalate medication. Given the diagonal in
Fig. 1, group 3 had above average willingness to de-
escalate, whereas group 1 was somewhat below average.
Willingness to de-escalate for group 2 was in general
above average for patients at the left side of the figure
(patients 1–48) and less than average for patients at the
right side (patients 49–96). A simple analysis to see
whether differences related to age, sex or practice-
related factors (Table 5) did not reveal particular
Table 4 Preference of doctors for de-escalation of DMARDs by subgroups based on answering patterns
Group 1
n = 48
Group 2
n = 22
Group 3
n = 26
Group 4
n = 30
Group 5
n = 30
β SE β SE β SE β SE β SE
Opt-out1 chosen 38% 21% 9% 1% 53%
Opt-out1 -2.78*** 0.23 -5.33*** 0.97 -4.98*** 0.83 -5.70*** 0.64 -4.72*** 0.41
DAS≤ 3.22 -0.59*** 0.15 -1.60** 0.49 -2.55*** 0.57 -0.59*** 0.15 -1.87*** 0.27
Swollen joint count
13 -1.01*** 0.19 -3.24*** 0.59 -1.02 0.53 -0.79*** 0.19 -3.53*** 0.48
23 -1.90*** 0.22 -6.06*** 0.99 -0.63* 0.28 -1.25*** 0.21 -3.92*** 0.51
Patient history
Erosive disease4 -1.27*** 0.20 -0.73 0.40 -1.23** 0.38 -0.58* 0.24 -1.29*** 0.43
Remission difficult4 -1.08*** 0.20 -0.95* 0.46 -1.42** 0.42 -0.44 0.27 -1.79*** 0.37
Erosive + remission difficult4 -2.80*** 0.25 -1.14 0.62 -2.99*** 0.60 -1.29*** 0.30 -2.79*** 0.40
Remission duration 6 months5 -0.41* 0.16 -1.17*** 0.40 -0.52 0.31 -0.17 0.14 -3.74 -
Patient not willing to de-escalate at start of visit6 -1.61*** 0.20 -1.05*** 0.30 -0.98** 0.30 -1.14*** 0.13 -1.49*** 0.27
Class probabilities, median (range) 0.99 (0.55 – 0.99) 0.99 (0.55 – 0.99) 0.94 (0.58 – 0.99) 0.99 (0.77 – 0.99) 0.98 (0.57 – 0.99)
β beta coefficient, SE standard error, DAS Disease Activity Score
*p < 0.05; **p < 0.01; ***p < 0.001
1This option was included in case a rheumatologist did not want to de-escalate DMARDs in either of the patients presented in a pair
2Reference DAS < 2.6
3Reference no swollen joints
4Reference easy remission and no erosions
5Reference remission duration 1 year
6Reference patient willing to de-escalate DMARDs at start of visit
Fig. 1 The probability rheumatologists choose to taper specific patients, shown for 96 unique patient profiles. Overall probability (average for all
rheumatologists, orange rounds) and probabilities by subgroups (other shapes) are shown
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characteristics of doctors. Being a trainee was associated
with lower preference to de-escalate.
After the decision whether to de-escalate or not, the
rheumatologists were presented with the choice which
DMARDs to de-escalate. Three options were presented:
de-escalating the TNF blocker, de-escalating methotrex-
ate (MTX) or de-escalating MTX to half the dose
followed by de-escalating the TNF blocker. Of de-
escalation strategies, rheumatologists chose de-escalating
the TNF blocker in the majority of cases (61%), followed
by de-escalating the TNF blocker after de-escalating
MTX to half dosage (33%).
Discussion
By semi-structured interviews, we identified five patient
characteristics rheumatologists take into account in their
decision to de-escalate DMARDs: number of swollen joints,
presence of DAS remission/LDA, patient history, duration
of remission/LDA and patient willingness to de-escalate.
Using a discrete choice experiment among Dutch rheuma-
tologists, number of swollen joints and patient history were
identified as factors of greatest importance. However, rheu-
matologists were not uniform in their decision to de-
escalate DMARDs. Based on a further (latent class) analysis
of the answering patterns, five subgroups of rheumatolo-
gists were identified that traded off patient characteristics
differently in their decision to de-escalate: (1) rheumatolo-
gists that always tapered, (2) rheumatologists tapering in
the absence of swollen joints, (3) rheumatologists tapering
in the absence of swollen joints and in the presence of a fa-
vorable patient history, (4) rheumatologists tapering in case
of DAS remission and favorable patient history, and (5)
rheumatologists taking into account all factors. That het-
erogeneity among rheumatologists exists with respect to
decision-making was further demonstrated by calculating
the probability rheumatologists would decide to de-escalate
medication for 96 unique patient profiles (Fig. 1). This
showed that subgroup probabilities were highly variable for
most of the profiles, especially those for which one or more
characteristics were less favorable (e.g., presence of one ra-
ther than no swollen joints or DAS LDA rather than DAS
remission). This means that no general consensus exists on
which patients are suitable for de-escalation. Eliciting de-
tails on rheumatologist subgroups resulted in mixed demo-
graphic characteristics, so other person-related factors are
likely to play a role. We only observed that trainees were
less willing to taper, possibly due to lack of experience and
confidence. Of de-escalation strategies rheumatologists
could choose from, de-escalating the TNF blocker first and
de-escalating the TNF blocker after reducing MTX to half
dosage were chosen in 94% of cases.
To date there is no standardized way to determine the
patient for whom de-escalation of DMARD therapy is
appropriate [8]. Of clinical factors, conflicting results
have been reported for deeper remission [14, 15] and
shorter disease duration [14–16] to be associated with
successful tapering, while observations from the COR-
RONA registry suggested that a rapid response to
DMARDs is associated with better maintenance of re-
mission when the agents are tapered later on [8, 17]. In
this DCE, rheumatologists regarded presence of swollen
joints, a patient history of erosive disease and difficulties
achieving remission and patient fulfilling DAS LDA
rather than remission as most important factors to not
de-escalate. Although swollen joints may be regarded as
a direct indication of inflammation and contraindication
for de-escalation, this is not necessarily true for the
DAS28 score itself, which could be high because of psy-
chosocial distress or comorbidities. Rheumatologists in
clinical practice may therefore sometimes decide to de-
escalate in case of DAS LDA in the absence of other
signs of inflammation. Future research may aid to clarify
which clinical factors are really important for predicting
successful de-escalation. Ultrasound [18–20] or bio-
markers [14, 21] may have an additional role in detect-
ing in which patients subclinical synovitis is still present
Table 5 Characteristics of subgroups
Group 1
n = 48
Group 2
n = 22
Group 3
n = 26
Group 4
n = 30
Group 5
n = 30
p*
Age (years), median (IQR) 43 (35–51) 49 (40–56) 39 (35–45) 50 (40–60) 41 (37–52) 0.038
Female, n (%) 22 (51%) 12 (55%) 15 (60%) 15 (50%) 20 (67%) 0.663
Trainee, n (%) 11 (26%) 2 (9%) 7 (29%) 1 (3%) 7 (26%) 0.051
Work experience (years), median (IQR) 7 (0–15) 13 (5–25) 5 (0–8) 12 (5–25) 4 (0–18) 0.027
Self-reported number of RA patients in practice,
median (IQR)
375 (100–800) 425 (200–1100) 450 (100–2000) 300 (200–1000) 300 (100–500) 0.492
Self-reported prevalence of biological treatment
among RA patients in practice, median (IQR)
23 (20–30) 20 (20–33) 30 (20–30) 29 (20–33) 20 (15–30) 0.641
Working in academic hospital, n (%) 9 (21%) 4 (18%) 6 (24%) 5 (17%) 7 (23%) 0.955
No data, n (%) 5 (10%) 0 (0%) 2 (8%) 1 (3%) 3 (10%) <0.001
RA rheumatoid arthritis
*Kruskall-Wallis test
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increasing the risk of flare after treatment withdrawal. It
would also be of interest to study whether (a combin-
ation of ) clinical, ultrasonographic and/or serum factors
can adequately predict which patients can successfully
de-escalate treatment.
This study was conducted using a DCE, which in com-
parison to other quantified preference techniques, bears
most resemblance to real-world decision-making [22]. A
strength of this design is that several patient characteris-
tics can be evaluated at once in which the weight of each
characteristic contributes to the decision to de-escalate
medication. Another strength of this study is that we
identified relevant characteristics using semi-structured
interviews with a random sample of rheumatologists to
identify relevant factors (characteristics and levels) for
the DCE questionnaire. As no new factors were men-
tioned during the final interviews, we assumed that
saturation was reached and hence no important factors
had been missed. One inherent limitation of a DCE is
that rheumatologists were asked to evaluate virtual RA
patients on screen. Consequently, as the decision to de-
escalate does not have real clinical implications, rheuma-
tologists may have been more risk-taking than they
would be when dealing with real patients. This could
then have resulted in an overestimation of rheumatolo-
gists’ willingness to de-escalate. Another limitation of
this study is that, although the majority of rheumatolo-
gists attending the annual conference participated in the
study, response rates were low for rheumatologists not
attending the conference that were invited to participate
from home. Although this could for a large part be ex-
plained by the method of recruitment, we could not fully
exclude the possibility of a relationship between non-
responders and tendency to de-escalate DMARDs.
In designing the questions for the DCE we made sev-
eral choices that need clarification. We refrained from
including side effects in the decision to de-escalate.
Several rheumatologists remarked that presence of side
effects is relevant in the decision of de-escalation ther-
apy. Although we agree, this is likely to influence the
decision to de-escalate a particular medicine first due to
side effects, it not necessarily relates to the decision of
de-escalation in patients achieving LDA or remission.
The presence of severe side effects would likely result in
de-escalation or switching medication before sustained
remission or LDA is achieved.
Second, a simple choice was given on what to de-
escalate. Rheumatologists could choose between de-
escalating the TNF inhibitor or MTX completely, or to
de-escalate the TNF inhibitor completely after reducing
MTX to half dosage. As more strategies are imaginable,
different strategies can and will be adopted in reality.
Therefore, more work on preference of what to de-
escalate first given both the medication characteristics
and patient characteristics would help to further under-
stand de-escalation of therapy decisions.
Third, due to the definition of levels assigned to the
disease characteristics, the relative importance of charac-
teristics could change if levels had been defined differ-
ently (e.g., remission duration of 2 years rather than
1 year). Therefore, the relative importance of character-
istics can only be interpreted taking the definition of the
levels into consideration.
Conclusions
Swollen joint count (SJC) and patient history were the
most important characteristics rheumatologists take into
consideration in the decision to de-escalate. However rheu-
matologists are not uniform in their decision on whom to
de-escalate. Five subgroups of rheumatologists could be
identified: those that taper (1) always, (2) in absence of
swollen joints, (3) in absence of swollen joints and favor-
able patient history, (4) if DAS remission and favorable
patient history, and (5) taking into account all factors.
To improve uniform decision-making in the future,
more research is needed assessing the predictive value of
patient characteristics for successful de-escalation of
DMARDs.
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